Production (Stage)
FibroBiologics, Inc.
FBLG
$0.8087
-$0.0638-7.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 65.97% | 32.30% | -114.41% | -154.12% | -245.63% |
| Total Depreciation and Amortization | 24.90% | 31.12% | 37.16% | 79.58% | 151.58% |
| Total Amortization of Deferred Charges | -- | -- | -100.00% | -100.00% | -99.26% |
| Total Other Non-Cash Items | -136.08% | -120.63% | 292.76% | 678.03% | 1,800.47% |
| Change in Net Operating Assets | -220.94% | 13.39% | 336.23% | 795.51% | 1,972.00% |
| Cash from Operations | -49.32% | -85.92% | -74.60% | -44.53% | -61.83% |
| Capital Expenditure | 51.01% | 62.83% | 82.35% | -511.25% | -698.21% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 51.01% | 62.83% | 82.35% | -511.25% | -698.21% |
| Total Debt Issued | 1,537.63% | -- | -- | -- | -73.30% |
| Total Debt Repaid | -299.13% | -- | -- | -- | -2.22% |
| Issuance of Common Stock | 66.30% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -100.00% | -94.58% | 59.81% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | 100.00% | -228.21% |
| Cash from Financing | 444.07% | 22.58% | -52.47% | -72.48% | -86.43% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 107.73% | -30.09% | -131.01% | -164.18% | -150.40% |